Below are summaries of recently published analyses from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). Click on the shortened citations to access the publications.

Breast Cancer – The TAILORx trial established that only a fraction of patients with early-stage, node-negative HR+/HER2- breast cancer benefit from adjuvant chemotherapy, leading to widespread use of genomic testing (Oncotype DX Recurrence Score®) to guide treatment. This post hoc analysis of patient-level data was conducted to assess whether TAILORx participants with high genomic risk (R >31) had improved outcomes when anthracyclines were added to taxane-based chemotherapy, and it explores the controversy around anthracycline use and long-term toxicity, particularly potentially irreversible cardiotoxicity. Impact of Anthracyclines in Genomic High-Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer. Chen N. Ann Oncol. November 2025.

Leukemia – Up to 70% of new acute myeloid leukemia (AML) cases occur in older patients. The E2906 randomized phase 3 trial focused on maintenance treatment for patients > 60 in remission, and its results serve as a key data set. Primary results were first reported in 2015, followed by an update in 2019, and quality-of-life data in 2023. This publication presents long-term outcomes data with 5 years of follow-up. Survival After Intensive Therapy or Clofarabine in Fit Older Adults with Acute Myeloid Leukemia: E2906 Phase 3 Trial. Foran JM. Blood. January 2026.

Lymphoma – The phase 1/2 study E4412 investigated brentuximab vedotin and nivolumab with or without ipilimumab for patients with relapsed or refractory classic Hodgkin lymphoma. This publication represents the primary results from the trial. A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients With Relapsed Hodgkin Lymphoma. Diefenbach CS. Blood. February 2026.

Lung Cancer – Biospecimen studies provide insight into patient selection and pharmacodynamics. To better understand participation in these optional studies, researchers analyzed enrollment patterns in two thoracic studies (E1505 and E5508). Of the 3,017 patients enrolled, 89% agreed to participate in at least one biomarker study, and 85% agreed to studies requiring future biospecimen collection. However, participation rates were lower among patients from historically underrepresented racial and ethnic groups, women, and those treated at community-based clinical sites. Participation in Lung Cancer Biospecimen Studies: An Analysis of the ECOG-ACRIN Phase 3 E1505 and E5508 Clinical Trials. Wang Y. Lung Cancer. April 2026.

NCI-MATCH – Arm H played a key role in the US Food and Drug Administration’s tumor-agnostic regulatory approval in 2022 for the combination of dabrafenib and trametinib in patients with BRAF^V600-mutated solid tumors. Following this, an expansion cohort study was conducted further to evaluate longer-term efficacy and safety in additional patients. The results confirm the clinical benefits of the combination, supporting the regulatory approval. Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF^V600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H. Salama AKS. JCO Precis Oncol. January 2026.

NCI-MATCH – Arm Z1E assessed larotrectinib, a selective small molecule inhibitor of TRK proteins. The study met its primary endpoint, demonstrating an objective response rate of 75% in NTRK fusion–positive tumors. Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E. Akhave NS. JCO Precis Oncol. February 2026.

NCI-MATCH – The oral tyrosine kinase inhibitor crizotinib was evaluated in tumors with MET amplification (Arm C1) and tumors with MET exon 14-deletion (Arm C2). Arm C1 met its primary endpoint, but Arm C2 did not. Crizotinib in Patients with Tumors With MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2. Coleman N. Clin Cancer Res. January 2026.

Prostate Cancer – The randomized phase 2 trial E2809 assessed the effectiveness of adding the AKT inhibitor MK-2206 to the anti-hormone therapy bicalutamide, compared with bicalutamide alone, in men with rising prostate-specific antigen (PSA) levels after primary treatment (biochemical recurrence). The hypothesis posited that combined inhibition of AKT and the androgen receptor (AR) could be more effective than AR inhibition alone, due to the additive effects on both pathways. This publication represents the primary results from the trial. Phase 2 Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809). Ferrari AC. Prostate. January 2026.